このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Edwards Lifesciences 将来の成長

Future 基準チェック /06

Edwards Lifesciences利益と収益がそれぞれ年間7.5%と8.4%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に23.9% 5.3%なると予測されています。

主要情報

5.1%

収益成長率

5.1%

EPS成長率

Medical Equipment 収益成長	18.4%
収益成長率	4.6%
将来の株主資本利益率	16.7%
アナリストカバレッジ	Good
最終更新日	25 Sep 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BOVESPA:E1WL34 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	6,593	1,702	1,584	1,875	16
12/31/2025	5,993	1,574	1,599	1,879	20
12/31/2024	5,961	1,403	1,767	2,073	8
6/30/2024	6,204	1,540	552	866	N/A
3/31/2024	6,114	1,428	251	528	N/A
12/31/2023	6,005	1,402	630	896	N/A
9/30/2023	5,362	1,341	775	1,042	N/A
6/30/2023	5,201	1,300	669	940	N/A
3/31/2023	5,279	1,451	972	1,239	N/A
12/31/2022	5,382	1,522	953	1,218	N/A
9/30/2022	5,364	1,459	1,040	1,309	N/A
6/30/2022	5,355	1,455	1,261	1,531	N/A
3/31/2022	5,357	1,539	1,428	1,725	N/A
12/31/2021	5,233	1,503	1,402	1,732	N/A
9/30/2021	5,095	1,477	1,409	1,758	N/A
6/30/2021	4,925	1,462	1,050	1,443	N/A
3/31/2021	4,474	851	717	1,148	N/A
12/31/2020	4,386	823	647	1,054	N/A
9/30/2020	4,369	794	692	1,057	N/A
6/30/2020	4,322	744	941	1,279	N/A
3/31/2020	4,484	1,108	1,087	1,389	N/A
12/31/2019	4,348	1,047	905	1,183	N/A
9/30/2019	4,152	774	809	1,073	N/A
6/30/2019	3,964	725	705	978	N/A
3/31/2019	3,821	765	523	777	N/A
12/31/2018	3,723	722	685	927	N/A
9/30/2018	3,634	712	754	998	N/A
6/30/2018	3,549	657	772	966	N/A
3/31/2018	3,447	560	N/A	1,024	N/A
12/31/2017	3,435	584	N/A	1,001	N/A
9/30/2017	3,315	745	N/A	838	N/A
6/30/2017	3,232	716	N/A	733	N/A
3/31/2017	3,150	657	N/A	726	N/A
12/31/2016	2,964	570	N/A	704	N/A
9/30/2016	2,867	552	N/A	607	N/A
6/30/2016	2,743	528	N/A	604	N/A
3/31/2016	2,601	515	N/A	584	N/A
12/31/2015	2,494	495	N/A	550	N/A
9/30/2015	2,441	463	N/A	539	N/A
6/30/2015	2,433	440	N/A	349	N/A
3/31/2015	2,391	874	N/A	957	N/A
12/31/2014	2,323	811	N/A	1,022	N/A
9/30/2014	2,241	777	N/A	1,040	N/A
6/30/2014	2,129	759	N/A	1,160	N/A
3/31/2014	2,071	306	N/A	511	N/A
12/31/2013	2,046	389	N/A	473	N/A
9/30/2013	2,020	405	N/A	476	N/A

アナリストによる今後の成長予測

収入対貯蓄率: E1WL34の予測収益成長率 (年間9.7% ) は貯蓄率 ( 9.9% ) を下回っています。

収益対市場: E1WL34の収益 ( 9.7% ) BR市場 ( 14% ) よりも低い成長が予測されています。

高成長収益: E1WL34の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: E1WL34の収益 ( 4.2% ) BR市場 ( 7.8% ) よりも低い成長が予測されています。

高い収益成長: E1WL34の収益 ( 8.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: E1WL34の自己資本利益率は、3年後には低くなると予測されています ( 18.3 %)。

Edwards Lifesciences 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Edwards Lifesciences Corporation Provides Earnings Guidance for the Third Quarter of 2024

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation Provides Earnings Guidance for the First Quarter and Full Year 2024

Edwards Lifesciences Corporation Reaffirms Earnings Guidance for the Year 2023 and Provides Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation Provides Earnings Guidance for Full Year 2023 and Fourth Quarter of 2023

Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023

Recent updates

Edwards Launches SAPIEN 3 With Alterra Prestent in Europe for Transcatheter Pulmonic Valve Implantation

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

Edwards Lifesciences Corporation Provides Earnings Guidance for the Third Quarter of 2024

Edwards Lifesciences Corporation (NYSE:EW) agreed to acquire the remaining unknown majority stake in Innovalve Bio Medical Ltd. for $300 million.

Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Edwards Lifesciences Corporation Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation to Report Q1, 2024 Results on Apr 25, 2024

Edwards Lifesciences Announces the Release of Data from the Hudle Study

Edwards Lifesciences Corporation, Annual General Meeting, May 07, 2024

Edwards Lifesciences Announces Large, Real-World Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR

Edwards Lifesciences Corporation Provides Earnings Guidance for the First Quarter and Full Year 2024

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Edwards Lifesciences Corporation to Report Q4, 2023 Results on Feb 06, 2024

Edwards Lifesciences Corporation Reaffirms Earnings Guidance for the Year 2023 and Provides Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares.

Clasp IID One-Year Data Confirm Safety and Efficacy of Edwards Pascal System for Degenerative Mitral Regurgitation

Edwards Lifesciences Corporation Provides Earnings Guidance for Full Year 2023 and Fourth Quarter of 2023

Edwards Lifesciences Corporation's Evoque Tricuspid Valve Replacement System Receives CE Mark

Edwards Lifesciences Corporation to Report Q3, 2023 Results on Oct 25, 2023

Edwards Lifesciences Corporation Announces the Results of the Eu-Hyprotect Registry

Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023

Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023

Edwards Lifesciences Announces Results of the EU-HYPROTECT Registry

Edwards' Aortic Valve with Resilia Tissue Shows Favorable Durability, Safety and Efficacy Outcomes in Seven Year Data

Edwards Lifesciences Corporation to Report Q4, 2022 Results on Jan 31, 2023

Edwards Lifesciences Corporation Provides Earnings Guidance for the Full Year 2023

Edwards Lifesciences Corporation, Annual General Meeting, May 11, 2023

Edwards Lifesciences Corporation Announces One-Year Data on Transfemoral Transcatheter Tricuspid Valve Replacement

Edwards Lifesciences Corporation to Report Q3, 2022 Results on Oct 27, 2022

Edwards Lifesciences Corporation Announces Results from CLASP IID

Edwards Lifesciences Corporation's Transcatheter Edge-To-Edge Repair Receives FDA Approval

Edwards Lifesciences Corporation Launches SAPIEN 3 Ultra Resilia Valve Following FDA Approval

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year of 2022

Edwards Lifesciences Corporation to Report Q2, 2022 Results on Jul 28, 2022

Edwards Lifesciences Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2022

Edwards Lifesciences Corporation to Report Q1, 2022 Results on Apr 26, 2022

Edwards Lifesciences Corporation's MITRIS RESILIA Valve Receives FDA Approval for Mitral Replacement Surgeries

Edwards Lifesciences Provides Earnings Guidance for the First Quarter and Full Year of 2022

Edwards Lifesciences Corporation Receives FDA Approval for SAPIEN 3 with Alterra Prestent for Transcatheter Pulmonic Valve Replacement

Edwards Lifesciences Corporation Provides Sales Guidance for Fiscal 2022

Edwards Lifesciences Announces Clinical and Economic Results from 3M Transcatheter Aortic Valve Replacement Economic Study and the Partner 3 Bicuspid Registry for SAPIEN 3 TAVR Study

Edwards Lifesciences Receives U.S. Food and Drug Administration Clearance for Hypotension Prediction Index Software for Noninvasive Acumen IQ Cuff

Edwards Lifesciences Corporation Presents Clinical Results from Transcatheter Mitral and Tricuspid Programs as Part of the Late-Breaking Clinical Trials at EuroPCR 2021

Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares.

Edwards Lifesciences Corporation Provides Earnings Guidance for the Full Year 2021

Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years

Edwards Lifesciences Corporation to Report Q4, 2020 Results on Jan 27, 2021

Edwards SAPIEN 3 TAVI Receives Expanded Approval in Canada

Edwards Lifesciences Corporation to Report Q3, 2020 Results on Oct 21, 2020

Sangamo BioSciences, Inc. has entered into a definitive asset purchase agreement to acquire angiogenesis program from and Edwards Lifesciences Corporation for $7.5 million.

Edwards Lifesciences Corporation to Report Q2, 2020 Results on Jul 23, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘